View in EDS

EDL6D, a bioactive peptide phenocopying SHBG-associated metabolic effects: a new preclinical lead compound for treating the metabolic dysfunction-associated fatty liver disease.

Saved in:
Bibliographic Details
Title: EDL6D, a bioactive peptide phenocopying SHBG-associated metabolic effects: a new preclinical lead compound for treating the metabolic dysfunction-associated fatty liver disease.
Authors: Alvarez-Guaita A; Diabetes and Metabolism Research Unit, Vall d' Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona and CIBERDEM (ISCIII), Pg Vall d'Hebron 119-129, Barcelona, 08035, Spain.; Endolipid Therapeutics S.L, Vall Hebron Institut de Recerca (VHIR), Barcelona, Spain., Cabrera-Serra J; Diabetes and Metabolism Research Unit, Vall d' Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona and CIBERDEM (ISCIII), Pg Vall d'Hebron 119-129, Barcelona, 08035, Spain., Perez-Gonzalez B; Diabetes and Metabolism Research Unit, Vall d' Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona and CIBERDEM (ISCIII), Pg Vall d'Hebron 119-129, Barcelona, 08035, Spain.; Endolipid Therapeutics S.L, Vall Hebron Institut de Recerca (VHIR), Barcelona, Spain., Salcedo-Allende MT; Human Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Fuertes-Rioja L; Diabetes and Metabolism Research Unit, Vall d' Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona and CIBERDEM (ISCIII), Pg Vall d'Hebron 119-129, Barcelona, 08035, Spain., Ramos-Perez L; Diabetes and Metabolism Research Unit, Vall d' Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona and CIBERDEM (ISCIII), Pg Vall d'Hebron 119-129, Barcelona, 08035, Spain., Hernandez C; Diabetes and Metabolism Research Unit, Vall d' Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona and CIBERDEM (ISCIII), Pg Vall d'Hebron 119-129, Barcelona, 08035, Spain., Simó R; Diabetes and Metabolism Research Unit, Vall d' Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona and CIBERDEM (ISCIII), Pg Vall d'Hebron 119-129, Barcelona, 08035, Spain.; Endolipid Therapeutics S.L, Vall Hebron Institut de Recerca (VHIR), Barcelona, Spain., Selva DM; Diabetes and Metabolism Research Unit, Vall d' Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona and CIBERDEM (ISCIII), Pg Vall d'Hebron 119-129, Barcelona, 08035, Spain. david.martinez.selva@vhir.org.; Endolipid Therapeutics S.L, Vall Hebron Institut de Recerca (VHIR), Barcelona, Spain. david.martinez.selva@vhir.org.
Source: Journal of translational medicine [J Transl Med] 2026 May 16; Vol. 24 (1). Date of Electronic Publication: 2026 May 16.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876 (Electronic) Linking ISSN: 14795876 NLM ISO Abbreviation: J Transl Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1479-5876
DOI:10.1186/s12967-026-08305-9